17 Jun 2009 16:44
|
| |||||
|
| |||||
| TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi | |||||
| 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii | SkyePharma Plc | ||||
| 2 Reason for the notification (please tick the appropriate box or boxes): | |||||
| An acquisition or disposal of voting rights | X | ||||
| An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached | |||||
| An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments | |||||
| An event changing the breakdown of voting rights | |||||
| Other (please specify): | |||||
| 3. Full name of person(s) subject to the notification obligation: iii | Fore Research & Management, LP | ||||
| 4. Full name of shareholder(s) (if different from 3.):iv | Credit Suisse Securities Deutsche Bank Securities | ||||
| 5. Date of the transaction and date on which the threshold is crossed or reached: v | June 12, 2009 | ||||
| 6. Date on which issuer notified: | June 16, 2009 | ||||
| 7. Threshold(s) that is/are crossed or reached: vi, vii | 18% | ||||
| 8. Notified details: | ||||||||||||||||
| A: Voting rights attached to shares viii, ix | ||||||||||||||||
| Class/type of shares if possible using the ISIN CODE | Situation previous to the triggering transaction | Resulting situation after the triggering transaction | ||||||||||||||
| Number of Shares | Number of Voting Rights | Number of shares | Number of voting rights | % of voting rights x | ||||||||||||
| Direct | Direct xi | Indirect xii | Direct | Indirect | ||||||||||||
| GB00B3BFNB64 | 375,951 | 1.62 | ||||||||||||||
| B: Qualifying Financial Instruments | ||||||||||||||||
| Resulting situation after the triggering transaction | ||||||||||||||||
| Type of financial instrument | Expiration date xiii | Exercise/ Conversion Period xiv | Number of voting rights that may be acquired if the instrument is exercised/ converted. | % of voting rights | ||||||||||||
| C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi | ||||||||||||||||
| Resulting situation after the triggering transaction | ||||||||||||||||
| Type of financial instrument | Exercise price | Expiration date xvii | Exercise/ Conversion period xviii | Number of voting rights instrument refers to | % of voting rights xix, xx | |||||||||||
| Convertible Bond converting into ISIN: GB00B3BFNB64 | May 4, 2024 | 3,774,663 | Nominal | Delta | ||||||||||||
| 16.22 | ||||||||||||||||
| Total (A+B+C) | ||||||||||||||||
| Number of voting rights | Percentage of voting rights | |||||||||||||||
| 4,150,614 | 17.84% | |||||||||||||||
| 9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: xxi | ||
| Fore Research & Management, LP is notifying solely in its capacity as a discretionary investment advisor to the private investment funds that it manages. As the general partner of Fore Research & Management, LP, Matthew Li, LLC is a parent undertaking of it. By virtue of Matthew Li's position as managing member and majority shareholder of Matthew Li, LLC, Matthew Li is a parent undertaking of it. | ||
| Proxy Voting: | ||
| 10. Name of the proxy holder: | ||
| 11. Number of voting rights proxy holder will cease to hold: | ||
| 12. Date on which proxy holder will cease to hold voting rights: | ||
| 13. Additional information: |
| |
| 14. Contact name: | Ari Burstein, General Counsel/Chief Compliance Officer | |
| 15. Contact telephone number: | +1 212-984-3870 | |
| Note: Annex should only be submitted to the FSA not the issuer | |
| Annex: Notification of major interests in share | |
| A: Identity of the persons or legal entity subject to the notification obligation | |
| Full name (including legal form of legal entities) | Fore Research & Management, LP |
| Contact address (registered office for legal entities) | 280 Park Avenue, 43rd Floor New York, NY 10017 United States |
| Phone number & email | 212-984-3870 ari.burstein@foreresearch.com |
| Other useful information (at least legal representative for legal persons) | Ari Burstein General Counsel/Chief Compliance Officer |
| B: Identity of the notifier, if applicable | |
| Full name | |
| Contact address | |
| Phone number & email | |
| Other useful information (e.g. functional relationship with the person or legal entity subject to the notification obligation) | |
| C: Additional information | |
| For notes on how to complete form TR-1 please see the FSA website. | |